Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stéphane Oudard

Showing results (1-10 of 263) with videos related to

Pageof 27
Sort By:
Anticancer Research|December 29, 2010
More than 4 years of progression-free survival in a patient with metastatic renal cell carcinoma treated sequentially with sunitinib, everolimus, sorafenib, and temsirolimusStéphane Oudard
Cancer Treatment Reviews|October 31, 2012
Progress in emerging therapies for advanced prostate cancerStéphane Oudard
The Lancet. Oncology|July 23, 2013
Docetaxel: time to reassess combination strategiesStéphane Oudard
Progres En Urologie : Journal De L'Association Francaise D'Urologie Et De La Societe Francaise D'Urologie|May 1, 2002
[Chemotherapy: principles and practice]Stéphane Oudard
Revue Medicale Suisse|June 14, 2013
[In the treatment of mCRPC, the question is to administer the right molecule to the right patient, at the right time]Stéphane Oudard
European Urology|February 16, 2008
Editorial comment on: combination of bevacizumab and docetaxel in docetaxel-pretreated hormone-refractory prostate cancer: a phase 2 studyStéphane Oudard
Bulletin Du Cancer|April 21, 2012
[Prostate cancer and chemotherapy: standards care and perspectives]Yacine Hadjarab, Stéphane Oudard
Nature Reviews. Urology|June 25, 2014
Prostate cancer: cabazitaxel--the taxane of choice in the new mCRPC landscape?Stéphane Oudard, Antoine Angelergues
European Urology Focus|October 9, 2024
Charting New Territories in Metastatic Prostate Cancer: A Convergence of Innovation and HopeConstance Thibault, Stéphane Oudard
Current Opinion in Urology|July 7, 2015
The role of rechallenge with targeted therapies in metastatic renal-cell carcinomaStéphane Oudard, Yann Vano
Pageof 27

Showing results (1-10 of 263) with videos related to

Sort By:
Pageof 27
Anticancer Research|December 29, 2010
More than 4 years of progression-free survival in a patient with metastatic renal cell carcinoma treated sequentially with sunitinib, everolimus, sorafenib, and temsirolimusStéphane Oudard
Cancer Treatment Reviews|October 31, 2012
Progress in emerging therapies for advanced prostate cancerStéphane Oudard
The Lancet. Oncology|July 23, 2013
Docetaxel: time to reassess combination strategiesStéphane Oudard
Progres En Urologie : Journal De L'Association Francaise D'Urologie Et De La Societe Francaise D'Urologie|May 1, 2002
[Chemotherapy: principles and practice]Stéphane Oudard
Revue Medicale Suisse|June 14, 2013
[In the treatment of mCRPC, the question is to administer the right molecule to the right patient, at the right time]Stéphane Oudard
European Urology|February 16, 2008
Editorial comment on: combination of bevacizumab and docetaxel in docetaxel-pretreated hormone-refractory prostate cancer: a phase 2 studyStéphane Oudard
Bulletin Du Cancer|April 21, 2012
[Prostate cancer and chemotherapy: standards care and perspectives]Yacine Hadjarab, Stéphane Oudard
Nature Reviews. Urology|June 25, 2014
Prostate cancer: cabazitaxel--the taxane of choice in the new mCRPC landscape?Stéphane Oudard, Antoine Angelergues
European Urology Focus|October 9, 2024
Charting New Territories in Metastatic Prostate Cancer: A Convergence of Innovation and HopeConstance Thibault, Stéphane Oudard
Current Opinion in Urology|July 7, 2015
The role of rechallenge with targeted therapies in metastatic renal-cell carcinomaStéphane Oudard, Yann Vano
Pageof 27